DR Congo Ebola outbreak exceeds 10,000 confirmed cases
Juste les faits

DR Congo Ebola outbreak exceeds 10,000 confirmed cases

Résumé

The Democratic Republic of the Congo has reported over 10,000 confirmed Ebola infections, with the disease spreading to multiple provinces and neighboring countries, while health officials launch a vaccine trial in the hardest-hit region.

The Democratic Republic of the Congo's health authorities announced on Tuesday that confirmed Ebola cases have risen to 10,060, including 4,887 deaths, giving the outbreak a case-fatality rate of 48.6 percent. The virus remains concentrated in the eastern Ituri province, which accounts for more than 70 percent of cases, but has spread to eight of the country's 26 provinces and 66 health zones.

A World Health Organization (WHO) regional report indicated that transmission, which had briefly declined in late September, intensified again in early October. Officials cited ongoing insecurity, population displacement and limited humanitarian access as factors hampering surveillance and response efforts.

Only about 12 percent of confirmed cases were identified among known contacts, according to Africa CDC official Wessam Mankoula, suggesting that some transmission chains remain undetected.

The outbreak has also led to imported cases in Uganda, France, Kenya and Nigeria. Kenya released 20 contacts of its first imported patient after a 21-day monitoring period, and reported nine confirmed cases overall, including two deaths. Nigeria evacuated its first patient to Switzerland and reported no current cases, while maintaining 52 contacts under observation. Ugandan authorities are cooperating with Nigeria and international partners to investigate the source of the Nigerian infection.

In response to the spread, Uganda reinstated traveler locator forms, tightened border screening and restricted transit for travelers with recent DRC exposure.

Scientists are advancing a vaccine effort as the first participant received a dose of a candidate vaccine in Bunia, the capital of Ituri, on Friday. The Phase 2/3 trial, named Tumaini, will assess the safety and efficacy of Ervebo—already approved for another Ebola strain—and two Bundibugyo-specific candidates developed by Moderna and the University of Oxford in partnership with the Serum Institute of India. > "If successful, this would be the first time we have clear evidence of vaccine efficacy against Bundibugyo virus," said WHO Health Emergencies Program executive director Chikwe Ihekweazu, describing the trial as a major advance.

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.